Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : CanSino Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Convidecia Air™ (homologous inactivated covid-19 vaccine) has proven to be an innovative solution that provides safe and effective protection for people through a needle-free, painless and non-invasive delivery without any serious adverse events observ...
Product Name : Convidecia
Product Type : Vaccine
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : CanSino Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : CanSino Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Aerogen® and CanSinoBIO agree on landmark development and commercial supply partnership for world’s first inhaled Covid-19 vaccine, Convidecia™ utilizing Aerogen’s proprietary vibrating mesh aerosol drug delivery technology.
Product Name : Convidecia
Product Type : Vaccine
Upfront Cash : Undisclosed
September 12, 2021
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : CanSino Biologics
Deal Size : Undisclosed
Deal Type : Partnership